RVL Pharmaceuticals Focuses on Scaling Upneeq as Market Momentum Builds
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
Designed for use with the Symani system, the suture features a shorter length and modified needle curvature to support precision in microsurgical and supermicrosurgical cases.